Pharma Capital

Abzena looks to a stronger second half after making sluggish start to financial year

The company is optimistic on the outlook for the second six months of the financial year with “good order cover and a high engagement level for new business”. That said, Abzena is unlikely to recover the entire shortfall
test tubes
The life sciences company said its long-term prospects remained strong

Life sciences group Abzena plc (LON:ABZA) said it expects revenue for the second half of the financial year to be “substantially stronger” than the first after getting off to a sluggish start.

In a trading update, the company said first-half turnover had been below expectations and only marginally ahead of the figure posted for the same period last year.

“The group's slower than expected start for the period can be attributed to lower volumes in certain areas of the business, a small number of large projects that are taking longer to complete than expected, and certain other projects being delayed until the second half of the year,” Abzena told investors.

READ: Abzena investors being rewarded for their financial backing of the life sciences group

The company is optimistic on the outlook for the second six months of the financial year with “good order cover and a high engagement level for new business”.

That said, Abzena is unlikely to recover the entire shortfall. “The board, therefore, expects revenue for the full year to be materially lower than previously expected, with consequential impact on reported loss,” investors were told.

“Notwithstanding this slow start to the year, the board remains optimistic that the group's long term prospects remains strong.”

READ: Abzena licenses prostate cancer antibody to Australian radiotherapy firm

View full ABZA profile

Abzena plc Timeline

View All

Related Articles

generic pill and bottle shot to denote Alliance's products
The company has made the transition from a business capitalised at £90mln to company now worth around a quarter of a billion pounds - but has the market at large picked up on (and priced in) the transformation?

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.